Impact of Albumin on Coagulation Competence and Hemorrhage During Major Surgery

Rasmussen, Kirsten C; Højskov, Michael; Johansson, Pär I.; Kridina, Irina; Kistorp, Thomas Klint; Salling, Lisbeth Nerstrøm; Nielsen, Henning Morris Bay; Ruhnau, Birgitte Krogsgård; Pedersen, Tom; Secher, Niels H.

Published in:
Medicine (Baltimore)

DOI:
10.1097/MD.0000000000002720

Publication date:
2016

Citation for published version (APA):
Rasmussen, K. C., Højskov, M., Johansson, P. I., Kridina, I., Kistorp, T. K., Salling, L., ... Secher, N. H. (2016). Impact of Albumin on Coagulation Competence and Hemorrhage During Major Surgery: A Randomized Controlled Trial. DOI: 10.1097/MD.0000000000002720
Impact of Albumin on Coagulation Competence and Hemorrhage During Major Surgery

A Randomized Controlled Trial

Kirsten C. Rasmussen, MD, Michael Højskov, MD, Pär I. Johansson, MD, DMSc, MPA, Irina Kridina, MD, Thomas Kistorp, MD, Lisbeth Salling, MD, PhD, Henning B. Nielsen, MD, DMSc, Birgitte Ruhnau, MD, Tom Pedersen, MD, DMSc, and Niels H. Secher, MD, DMSc

Abstract: For patients exposed to a massive blood loss during surgery, maintained coagulation competence is important. It is less obvious whether coagulation competence influences bleeding during elective surgery where patients are exposed to infusion of a crystalloid or a colloid.

This randomized controlled trial evaluates whether administration of 5% human albumin (HA) or lactated Ringer solution (LR) affects coagulation competence and in turn blood loss during cystectomy due to bladder cancer.

Forty patients undergoing radical cystectomy were included to receive either 5% HA (n = 20) or LR (n = 20). Nineteen patients were analyzed in the HA group and 20 patients in the lactated Ringer group.

Editor: Kwok Ho.
Received: October 1, 2015; revised: December 15, 2015; accepted: January 11, 2016.
From the Department of Anesthesiology (KCR, MH, IK, TK, HBHN, BR, NHS); Department of Urology (LS); Center of Head and Orthopaedic Surgery (TP); Rigshospitalet, University of Copenhagen; Department of Transfusion Medicine, Rigshospitalet and Department of Surgery, Denmark, and University of Texas Health Medical School, Houston, TX, USA (PIU).
Correspondence: Kirsten C. Rasmussen, Department of Anesthesiology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark (e-mail: dockcr@yahoo.com).
KCR contributed to conception and design of the study, acquisition, analysis, and interpretation of presented data, drafting the article, and final approval of the version to be published. MH contributed to acquisition, and interpretation of presented data, helped draft the manuscript. PIJ contributed to conception and design of the study, IK contributed to acquisition, analysis, and interpretation of presented data, helped draft the manuscript. LS participated in interpretation of presented data, helped draft the manuscript. HBHN contributed to interpretation of presented data, helped draft the manuscript. BR contributed to conception, acquisition, interpretation of presented data, helped draft the manuscript. TP contributed to statistical analysis, interpretation of presented data, helped draft the manuscript. TP contributed to statistical analysis, interpretation of presented data, helped draft the manuscript. NHS contributed to conception and design of the study, critical revision of the article for important intellectual content. All authors approved the final version to be published.
Trial registration: ClinTrials.gov (NCT02270723) and EuadrACT 2013–005350–29.
This study was supported by AP Møller’s (Maersk) Fond, The Augustinus Edith Olesen’s Legat, and by T & A Frimodt’s Fond.
The authors have no conflicts of interest to disclose.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000002720

INTRODUCTION

During surgery the circulation is supported by a crystalloid, often saline or lactated Ringer solution (LR), eventually supplemented by a colloid to delay when there is a need for blood transfusion. In contrast to colloids, colloids stay within the circulation and may even recruit fluid to the vasculature.1 It therefore remains an option to administer a colloid to bleeding patients perioperatively.2–4 On the other hand, synthetic colloids impair coagulation competence as exemplified by the use of hydroxyethyl starch (HES 130/0.4) during major surgery.5 A thrombelastography (TEG) analysis showed that HES reduced clot formation and strength (maximal amplitude [MA]) and doubled the perioperative blood loss when compared to the use of LR.6 Similarly, administration of Dextran reduced coagulation competence during cystectomy and clinically important hemorrhage (>1.5 L) appeared more often among the patients who received Dextran than LR.6

Human albumin (HA) might be expected to affect coagulation competence minimally but a meta-analysis addressing cardiac surgery7 found increased perioperative bleeding and need for transfusion with the use of albumin compared to administration of hydroxyethyl starch (HES 130/0.4). Albumin may reduce platelets activation and release of inflammatory mediators,8,9 but another meta-analysis found blood loss and...
need for blood transfusion increased by about 30% among patients who received HES 130/0.4 rather than albumin. One randomized controlled trial compared the effect of administration HA and LR during major surgery and found similar blood loss in the 2 groups of patients and yet increased need for transfusion of blood in the albumin treated group.

The present randomized controlled study aimed to further explore the relationship between the perioperative blood loss and coagulation competence during cystectomy with the use of either HA or LR to support the circulation. The hypothesis was that HA affects coagulation competence to such an extent that it increases the blood loss as compared to use of LR. In addition, we tested the hypothesis that TEG analysis is superior to predict the blood loss compared to plasma coagulation variables.

MATERIALS AND METHODS

Trial Design

This randomized controlled trial was approved by ClinicalTrials.gov (NCT02270723), the Danish Health and Medicine Authority (EudraCT 2013-005350-29), and the local Ethics Committee in the Capital Regional of Denmark (H-1-2013-142) and was registered by the Danish Data Protection Agency. The trial was monitored by the Agency for Good Clinical Practice at the University of Copenhagen and the Declaration of Helsinki criteria were followed.

Conduct of the trial and the safety of the participants were overseen by the authors who gathered the data that remained confidential throughout the process. The authors were involved in all stages of manuscript generation and vouched for completeness and accuracy. No third party influenced the study design, data analysis, or reporting.

Screening and randomization took place between April 8th 2014 and July 8th 2015. At least 24 hours before surgery written informed consent was obtained from the patients. We excluded patients from this investigator-initiated, prospective, blinded trial if consent was withdrawn. Forty patients scheduled for elective cystectomy were randomized to receive the recommended maximum volume (25 mL/kg) of either HA (Albumin, human, CSL Behring, GmbH, Marburg, Germany) or LR by computer-generated allocation sequence without blocks produced by the biostatistics Department (Figure 1). We included patients older than 18 years scheduled for elective cystectomy with no history of heart or hepatic insufficiency, disability of coagulation, intracerebral hemorrhage, or hemodialysis. If a patient used medication that was considered to affect coagulation competence, that medication was paused 5 days prior to surgery according to national guidelines.

Interventions

The primary design of intervention has been published previously. An intravenous line flushed with the randomized fluid was placed in an opaque bag together with the intravenous set to blind the surgical nurse who recorded the volume of lost blood. The patients were in general anesthesia by remifentanyl

---

FIGURE 1. Consort study flow diagram.
and propofol administration and monitored with a periphery arterial catheter connected to Nexfin device besides a central venous and epidural catheter – the latter for postoperative pain treatment.14

Normovolemia was established according to “goal directed fluid therapy” (GDT) criteria.15 Hemodynamic data were recorded after induction of anesthesia and insertion of the arterial catheter (T₀), before start of surgery (T₁), after resection of the urinary bladder (T₂), at the end of anesthesia (T₃), and 2 hours thereafter in the recovery room (T₄).

Arterial blood specimens were analyzed by TEG16 and we also analyzed blood specimens for hemoglobin, creatinine, plasma coagulation, and blood gas variables. Both groups of patients received either LR or SAG M if considered in need after plasma coagulation, and blood gas variables. Both groups of patients were analyzed in the group to which they were assigned (Table 1). The sample size was based on data from the study comparing the effect on hemorrhage during cystectomy on albumin infusion with the use of HES 130/0.4 versus LR. In that study, the blood loss was 2181 versus 1370 mL with an SD of 1190 versus 603 mL.5 The study was powered to detect a difference in blood loss of 800 mL between administration of HA and LR with a 2-sided alpha level of 0.05 and a power of 80% for t-test with correction for multiple comparisons. Consequently, a sample size of 20 patients per group was included.

The statistical analyses were performed before breaking the randomization code, and data were analyzed from the modified intention-to-treat population, defined as all randomly assigned patients except for those who could be excluded without the risk of bias (Figure 1). We used 2-sided or unadjusted Chi-square tests with odds ratio (OR), t-test, and Fisher exact test for continuous and dichotomous variables, respectively (SPSS version 20.0). Evaluation of differences was performed using χ² test for categorical data and analysis of variance or Mann–Whitney U-test and Wilcoxon signed ranks test for continuous data when appropriate. Results are presented as mean (SD) or median with range for skewed variables and a 2-sided P value < 0.05 was considered to indicate statistical significance. Correlations were evaluated by Spearman coefficient. A backwards multivariate linear regression analysis with Bonferroni correction for multiple comparisons was performed, including variables that were either found to be correlated with or expected to influence TEG and plasma hemostatic variables that were independently associated with albumin infusion during anesthesia. The variables included in the multivariate analyses were TEG-angle, TEG-maximum amplitude (TEG-MA), platelets, fibrinogen, aPPT, and INR. Results are presented as regression coefficients (β) with 95% confidence interval and t and P values.

**TABLE 1. Patient Characteristics and Baseline Laboratory Values and Perioperative Events**

| Preoperative status | All Patients (n = 39) | Albumin (n = 19) | Lactated Ringer (n = 20) | P Value |
|---------------------|----------------------|------------------|-------------------------|---------|
| Preoperative status |                      |                  |                         |         |
| Age, years          | 69 (9) (66–72)       | 69 (10) (64–73)  | 69 (8) (66–73)          | 0.84    |
| Males gender (n)    | 25 (64%)             | 12 (63%)         | 13 (65%)                | 0.91    |
| Body weight, kg     | 78 (14) (74–83)      | 77 (15) (70–84)  | 80 (12) (74–86)         | 0.48    |
| ASA (≥2)            | 6 (15%)              | 3 (16%)          | 3 (15%)                 | 0.73    |
| Cardiopulmonary disease (n) | 18 (46%) | 8 (42%) | 10 (50%) | 0.75 |
| TEG                 |                      |                  |                         |         |
| R-time, minute      | 4.7 (1.5) (4.3–5.1)  | 4.8 (0.8) (4.0–5.6) | 4.6 (0.8) (4.2–5.0) | 0.73    |
| Angle, degrees      | 72 (6) (70–74)       | 71 (8) (67–75)   | 73 (4) (71–74)          | 0.38    |
| MA, mm              | 65 (6) (62–67)       | 62 (6) (59–65)   | 67 (6) (64–69)          | 0.05    |
| Ly30, minute        | 1.6 (2.0) (0.9–2.2)  | 2.1 (2.4) (0.9–3.2) | 1.1 (1.4) (0.4–1.8) | 0.13    |
| Biochemistry        |                      |                  |                         |         |
| Platelets count, n/L| 241 (68) (219–264)   | 238 (82) (199–278) | 244 (54) (219–269) | 0.79    |
| Fibrinogen, μmol/L  | 10.8 (2.6) (9.9–11.6)| 10.6 (2.4) (9.5–11.8) | 10.9 (2.9) (9.5–12.2) | 0.78    |
| aPPT, second        | 29.1 (3.8) (27.9–30.3)| 30.1 (4.5) (27.8–32.3) | 28.3 (2.8) (27.0–29.5) | 0.14    |
| INR                 | 1.07 (0.1) (1.05–1.10)| 1.06 (0.1) (1.02–1.10) | 1.08 (0.1) (1.04–1.12) | 0.53    |
| Perioperative variables |                  |                  |                         |         |
| Anesthesia time, minute | 249 (165–375)       | 260 (165–375)   | 239 (165–300)          | 0.16    |
| Ephephrine, mg      | 30 (0–65)            | 23 (0–40)        | 37 (0–65)               | 0.004   |
| Complications (n)   | 13 (33%)             | 6 (32%)          | 7 (35%)                 | 0.82    |
| Reoperations (n)    | 6 (15%)              | 3 (16%)          | 3 (15%)                 | 0.95    |
| Hospital stay, days | 7 (3–90)             | 8 (5–90)         | 7 (3–20)                | 0.27    |
| Straight postoperative track | 19 (49%) | 9 (47%) | 10 (50%) | 0.87 |

Values are either numbers (n), percentages (%), mean for normally distributed variables with SD and 95% confidence interval, or medians with range for skewed data. P-value by univariate analysis. TEG R-time (rate of clot initiation), TEG angle (clot growth). aPPT = active partial thromboplastin time, ASA = American Society of Anesthesiologists, INR = international normalized ratio, Ly30 = Lysis after 30min, TEG = thrombelastography, TEG-MA = thrombelastography maximal amplitude.
RESULTS
There was no significant intergroup difference in baseline data including preoperative diagnoses between the 2 groups of patients (Figure 1 and Table 1). After induction of anesthesia, 3 patients (16%) in the albumin group were intravascular hypovolemic according to GDT criteria as compared to 1 patient (5%) in the crystalloid group (P = 0.34). In the colloid group, patients received 23.5 mL/kg (1125–2500) mL HA and 4 patients did not receive the full scheduled volume, because they were considered hemodynamic stable before the intended volume (25 mL/kg) was infused.

Fluid Administration and Blood Loss
The perioperative blood loss was 1658 (800–3300) mL in the albumin group and not significantly different in the LR group: 1472 (700–4330) mL, P = 0.45, Table 2. Furthermore, the number of patients exposed to what we considered a significant blood loss (>1500 mL) was similar in the albumin and in the LR group: 6 patients (33%) versus 5 patients (28%), P = 1.00. Table 2 also presents the IV administration of study and nonstudy fluids. Transfusion was initiated at a hemoglobin of 3.8 to 5.5 mmol/L and the transfusion of packed red blood cells was 235 (0–980) versus 80 (0–1100) mL in the albumin and LR group, respectively (P = 0.14). Thus, 6 patients (33%) in both groups were provided with blood transfusion.

The fluid balance was positive by 1095 (400–2460) mL in the albumin group and by 1687 (415–2850) mL in the LR group (P < 0.001), also with more patients in the LR group having a positive fluid balance that we considered significant, that is, exceeding 2000 mL: 9 patients versus 1 patient, OR = 14.7 (1.6–132.6), P = 0.016. Furthermore, the albumin group received less ephedrine than the LR group, 23 (0–40) mg versus 37 (0–65) mg, P = 0.004.

Hemodynamics
During anesthesia changes in MAP were similar in the 2 groups of patients, whereas HR increased more in the LR group (68 ± 18 to 81 ± 10) beats/min compared to the albumin group (67 ± 15 to 68 ± 14) beats/min, P < 0.002. SV increased in the albumin group (61 ± 14 to 76 ± 13) mL/beats compared to LR group (67 ± 14 to 66 ± 14) mL/beats, P = 0.038; however, CO was not significantly different between the 2 groups of patients.

Coagulation
The baseline values of TEG and biochemistry variables are given in Table 1. After cystectomy (T2) in the LR group, TEG-angle increased to 74 ± 3 compared to 69 ± 5 degrees in the albumin group, P < 0.01. The lowest values of TEG-MA was observed in the albumin group (60 ± 7 vs 68 ± 6) mm, P < 0.002. APPT decreased in the LR group to 27.9 ± 2.7 and to 31.4 ± 3.9 seconds in the albumin group, P < 0.003. There was no significant differences between the groups regarding R-time, Lysis after 30 min (Ly30), platelets, INR, or coagulation factor II, VII, X.
At the end of anesthesia (T3) TEG-angle in the LR group increased to 74 ± 5 compared with 69 ± 5 degrees in the albumin group, P < 0.003. The lowest value of TEG-MA was observed in the albumin group (59 ± 6 vs 67 ± 6) mm, P < 0.001. Platelets decreased in both groups of patients, mainly in the albumin group (185 ± 51) 10^9/L compared to the LR group (232 ± 49) 10^9/L, P < 0.008. APPT decreased in the LR group to 26.0 ± 32.7 seconds compared to the albumin group 31.8 ± 6.2 seconds, P < 0.001, and INR increased more in the albumin group (to 1.34 ± 0.20) compared with the LR group (to 1.14 ± 0.10), P < 0.001. There was no significant difference in R-time and Ly30, between the groups of patients.
In the recovery room (T4) the TEG-angle was 74 ± 4 compared with 71 ± 4 degrees in the albumin group, P < 0.03. The lowest values of TEG-MA was observed in the albumin group compared to the LR group (60 ± 6 vs 65 ± 7) mm, P < 0.008. Platelets decreased in both groups of patients, mainly after albumin (185 ± 51 vs 223 ± 48) 10^9/L, P < 0.03. APPT decreased in the LR group to 25.0 ± 3.2 seconds compared to the albumin group (30.6 ± 4.9) seconds, P < 0.001, whereas INR increased more in the albumin group (to 1.26 ± 0.10) compared with the LR group (to 1.14 ± 0.08), P < 0.001. Likewise, in the recovery room, the R-time and Ly30 were without differences between the groups. The decrease in hemoglobin was not significantly different in the albumin group compared to the LR group (7.4 ± 1.3 to 5.9 ± 0.8) versus (7.8 ± 1.1 to 6.4 ± 1.1) mmol/L, P < 0.12.

Correlations
Correlation between blood loss and albumin infusion during anesthesia versus coagulation variables is shown in Table 3. The changes in TEG-angle and TEG-MA from T1 to T3 were correlated to administration of albumin as was plasma coagulation variables. The perioperative blood loss was related to TEG-angle, TEG-MA, and platelets, whereas R-time, Ly30, aPPT, and INR demonstrated poor correlations.

Multivariate Linear Regression Analysis of the Association between Hemorrhage, Albumin Administration Versus Coagulation Competence
Independent association between bleeding and albumin infusion compared to reduced coagulation competence was evaluated by multivariate linear regression, including only univariate significant variables. The blood loss was independently associated with reduced TEG-MA, while both reduced TEG-MA and the biochemistry variables: aPPT and INR were
TABLE 3. Spearman Correlation of Changing in (TEG Values and Plasma Coagulation Tests (from T1 to T3) Related to Perioperative Bleeding and Albumin Administration in the Randomized Trial

|                  | Bleeding          | Albumin Infusion |
|------------------|-------------------|------------------|
|                  | r                  | P                | r               | P               |
| TEG angle        | −0.34 (0.03)       | 0.03             | −0.33 (0.03)    | 0.03            |
| TEG-MA           | −0.36 (0.02)       | 0.01             | −0.40 (0.01)    |                 |
| TEG R-time       | −0.26 (0.11)       | 0.37             | 0.15 (0.015)    | 0.04            |
| Ly30             | 0.12 (0.47)        | 0.80             | −0.04 (0.80)    |                 |
| Platelets count  | −0.38 (0.02)       | 0.002            | −0.48 (0.002)   |                 |
| Fibrinogen       | −0.28 (0.08)       | 0.80             | −0.47 (0.003)   |                 |
| aPPT             | 0.10 (0.51)        | 0.40             | 0.40 (0.01)     | 0.01            |
| INR              | 0.22 (0.19)        | 0.63             | <0.001          |                 |

TEG R-time (rate of clot initiation, minutes); TEG angle (clot growth, degrees). aPPT = active partial thromboplastin time (seconds), INR = international normalized ratio, Ly30 = Lysis after 30 min, TEG = thrombelastography, TEG-MA = thrombelastography maximal amplitude (mm).

TABLE 4. Multivariate Linear Regression Analyses of Association Between Perioperative Bleeding and Administration of Albumin Evaluated by TEG and Conventional Plasma Coagulation Variables (Changes from T1 to T3)

|                  | 95% CI for β | T   | P-Value |
|------------------|--------------|-----|---------|
| Bleeding         |              |     |         |
| TEG angle        | −0.01 (0.01) | 1.15| 0.26    |
| TEG-MA           | −0.02 (0.01) | 1.30| 0.042   |
| Platelets count  | −0.009 (0.002) | 0.61| 0.54    |
| Albumin administration |          |     |         |
| TEG angle        | −0.01 (0.04) | 0.19| 0.85    |
| TEG-MA           | −0.08 (0.04) | 2.27| 0.029   |
| Platelets count  | −0.005 (0.003) | 2.23| 0.09    |
| Fibrinogen       | −0.01 (0.11) | 0.13| 0.89    |
| aPPT             | 0.05 (0.02)  | 2.38| 0.022   |
| INR              | 2.96 (1.51)  | 2.25| 0.033   |

Regression coefficients (β) with SE; t and P-values displayed for the multivariate model. Multivariate linear regression models including only univariate significant variables from Table 3. TEG angle (clot growth, degrees). aPPT = active partial thromboplastin time, CI = confidence interval, INR = international normalized ratio, SE = standard errors, TEG = thrombelastography, TEG-MA = thrombelastography maximal amplitude.

Outcome

The postoperative course and number of treated complications were similar in the 2 groups of patients (Table 1).

DISCUSSION

This randomized controlled study used either HA or LR to support the circulation during cystectomy according to individualized goal-directed principles without demonstrating significant difference in perioperative bleeding or on outcome. Yet, perioperative hemorrhage was related to the TEG variable MA, but not to plasma coagulation variables.

Even though albumin is the most abundant protein in plasma and administration to patents therefore might be considered to be safe, there has been concern about the use of albumin to support the circulation during surgery. HA has been used without reports of viral infections, but in a systematic review including 1419 critically ill patients in 30 studies, the use of albumin seemed to increase mortality. Yet, the use of albumin was not mentioned in the comments from European Medicine Agency on the use of colloids and there has been no suggestion of banning albumin solutions. Albumin does not affect outcome, including mortality, in intensive care when compared to the use of saline. In support, blood loss during cardiac surgery is similar when administering albumin and LR. In contrast to the experience from cardiac surgery, the present study did not demonstrate increased need for administration of blood products with the use of albumin.

In this randomized controlled study comparing administration of LR versus albumin, both TEG-angle, TEG-MA and plasma coagulation variables were correlated to albumin infusion (Table 3), and these variables were used in the Spearman correlation analysis to design a multivariable regression analysis. Changes in TEG-MA and the biochemistry variables aPPT and INR were the only independent variables associated with infusion of albumin in line with the data from Skhirtladze et al who showed maximal clot firmness lower in the albumin compared to LR group when assessed in a postoperative evaluation.

Evaluation of coagulation competence remains debated. For trauma patients it is recommended that TEG rather than conventional plasma coagulation tests is used because TEG allows for a fast result but here the blood loss was correlated to TEG-MA rather than to plasma coagulation variables.

It may seem an advantage to administer albumin rather than LR as the postoperative fluid balance was 54% higher (1095 vs 1687) mL, P < 0.001 in the LR group. A positive correlation between TEG-MA and blood loss. Change in plasma TEG-MA from start (T1) to end of anesthesia (T2) in patients receiving lactated Ringer solution (A) or albumin (B). r = −0.36 (95% CI −0.62 to −0.10), P = 0.02 Regression lines shown with 95% confidence interval. CI = confidence interval, TEG-MA = thrombelastography maximal amplitude.
postoperative fluid balance has been related to gut edema and may contribute to intestinal dysfunction, postoperative complications and therefore extended hospital stay.\textsuperscript{24,25} On the other hand, the volume balance that maintains the central blood volume during and after surgery has not been determined. We suggest that such an evaluation is made, for example, by echocardiographic determination of ventricular filling or determination of which volume load that would maintain plasma atrial natriuretic peptide as an indication of a stable central blood volume.\textsuperscript{26}

There are limitations to this investigation. The volume used for GDT influences the estimate of the deficit. We used 200 mL, reflecting the volume used in most RCT studies, but the volume may be related to the weight, body mass index, age, and health of the patient.\textsuperscript{27} Besides, the study has a short observation period and a larger cohort may be needed to evaluate an effect of albumin versus LR on complications and survival.

CONCLUSION

The results suggest that the perioperative use of 5% HA compared to LR to support the circulation during cystectomy reduces the postoperative volume surplus but affects coagulation competence, but not to an extent that albumin affects bleeding or outcome measures. The results suggest that the perioperative use of 5% HA compared to LR only affects coagulation competence and blood loss little during major surgery. Also the use of HA reduced the postoperative volume surplus, but not the incidence of postoperative complications, or hospital stay.

REFERENCES

1. Zaar M, Lauritzen B, Secher NH, et al. Initial administration of hydroxyethyl starch vs. lactated Ringer after liver trauma in the pig. \textit{Br J Anaesth.} 2009;102:221–226.

2. Johansson PI, Stensballe J. Hemostatic resuscitation for massive bleeding: the paradigm of plasma and platelets – a review of the current literature. \textit{Transfusion.} 2010;50:701–710.

3. Gruen RL, Brohi K, Schreiber M, et al. Hemorrhage control in severely injured patients. \textit{Lancet.} 2012;380:1099–1108.

4. Lunde J, Stensballe J, Wikkelso A, et al. Fibrinogen concentrate for bleeding – a systematic review. \textit{Acta Anaesthesiol Scand.} 2014;58:1061–1074.

5. Rasmussen KC, Johansson PI, Hoegskov M, et al. Hydroxyethyl starch reduces coagulation competence and increase blood loss during major surgery. Results from a randomized controlled trial. \textit{Ann Surg.} 2014;2:249–254.

6. Rasmussen KC, Hoegskov M, Johansson PI, et al. Coagulation competence for predicting perioperative haemorrhage in patients treated with lactated Ringer’s vs Dextran – a randomized controlled trial. \textit{BMC Anesthesiol.} 2015;15:178.

7. Jacob M, Fellahi J, Chappell D, et al. The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis. \textit{Crit Care.} 2014;18:656.

8. Russell JA, Navickis RJ, Wilkes MM. Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. \textit{J Cardiothorac Vasc Anesth.} 2004;18:429–437.

9. Adrian K, Melgren K, Skogby M, et al. The effect of albumin priming solution on platelet activation during experimental long-term perfusion. \textit{Perfusion.} 1998;13:187–191.

10. Navickis RJ, Haynes GR, Wilkes MM. Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a meta-analysis of randomized trials. \textit{J Thorac Cardiovasc Surg.} 2012;144:223–230.

11. Skhirtladze K, Base EM, Lassnig A, et al. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer’s lactate on blood loss and coagulation after cardiac surgery. \textit{Br J Anaesth.} 2013;112:255–264.

12. ICH Steering Committee. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline for Good Clinical Practice. 3rd ed. London, UK: Brookwood Med Pub; 1998.

13. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (6th Edition). \textit{Chest.} 2008;133:2995–3398.

14. de Vaal JB, de Wilde RB, van den Berg PC, et al. Less invasive determination of cardiac output from the arterial pressure by aortic-catheterized pulse contour. \textit{Br J Anaesth.} 2005;95:326–331.

15. Bundgaard-Nielsen M, Holte K, Secher NH, et al. Monitoring of intraoperative fluid administration by individualized goal-directed therapy. \textit{Acta Anaesthesiol Scand.} 2007;51:331–340.

16. Johansson PI, Svendsen MS, Salado J, et al. Investigation of the thrombin-generating capacity, evaluated by thrombogram and clot formation evaluated by thrombelastography of platelets stored in the blood bank for up to 7 days. \textit{Vox Sang.} 2008;94:113–118.

17. Niemi TT, Miyashita R, Yamakage M. Colloid solutions: a clinical update. \textit{J Anesth.} 2010;24:913–925.

18. The Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. \textit{BMJ.} 1998;317:235–240.

19. Arunachalam L, MacFie J. Colloid versus crystalloid fluid therapy in surgical patients. \textit{BJS.} 2015;102:145–147.

20. Finfer S, Bellomo R, Boyce N, et al., SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. \textit{N Engl J Med.} 2004;350:2247–2256.

21. Ägren A, Wikman AT, Holmström M, et al. Thromboelastography (TEG®) compared to conventional coagulation tests in surgical patients – a laboratory evaluation. \textit{Scand J Clin Lab Invest.} 2013;73:214–220.

22. Pekelharing J, Furck A, Banya W, et al. Comparison between thromboelastography and conventional coagulation tests after cardiopulmonary bypass: a meta-analysis of randomized trials. \textit{Ann Surg.} 2012;256:476–486.

23. Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thromboelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. \textit{Ann Surg.} 2012;256:476–486.

24. Bundgaard-Nielsen M, Secher NH, Kehlet H. ‘Liberal’ vs. ‘restrictive’ intraoperative fluid therapy: a critical assessment of the evidence. \textit{Acta Anaesthesiol Scand.} 2009;53:843–851.

25. Corcoran T, Rhodes JE, Clarke S, et al. Intraoperative fluid management strategies in major surgery: a stratified meta-analysis. \textit{Anesth Analg.} 2012;114:640–651.

26. Matzen S, Perko G, Groth S, et al. Blood volume distribution during head-up tilt induced central hypovolaemia in man. \textit{Clin Physiol.} 1991;1:411–422.

27. Bundgaard-Nielsen M, Jørgensen CC, Secher NH, et al. Functional intravascular volume deficit in patients before surgery. \textit{Acta Anaesthesiol Scand.} 2010;54:464–469.